APOLLO: SLN360 Clears First Major Hurdle, Hammering Lp(a)

The results add to growing enthusiasm for achieving the 'holy grail' of a lipoprotein(a)-specific lowering agent, but whether it will reduce cardiovascular risk remains unknown.
Medscape Medical News

source https://www.medscape.com/viewarticle/971491?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?